CLOs on the Move

Q2 Solutions

www.q2labsolutions.com

 
Q² Solutions, a Quintiles Quest joint venture Launched in 2015, Q² Solutions (pronounced Q-squared) is a leading global clinical trials laboratory services organization. We help biopharmaceutical, medical device and diagnostics customers improve human health through innovation that transforms science and data into actionable medical insights. Q² Solutions is a quality driven, responsive partner with strong global experience and deep scientific and medical expertise. The Q² Solutions joint venture was formed by Quintiles and Quest Diagnostics, combining the best of each parent organizations clinical trials laboratory services capabilities.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Rep Fitness

REP Fitness is a home and commercial equipment supplier that specializes in strength and conditioning equipment. No matter what space youre working out in, REP has you covered.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic

URAC

URAC is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

PT Plus

Providing cutting edge therapeutic solutions to you, your family and friends.

Cincinnati Group Health Associates

Cincinnati Group Health Associates, Inc. is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, & Biotech sector.